The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Tariffs would also increase costs for Florida seniors. They’d drive up costs for Medicare, which is one of the largest drug ...

A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen ...

Q1 2025 Management View CEO Stephane Bancel highlighted that Q1 revenues were $0.1 billion, with a net loss of $1 billion, ...

Experts champion medically integrated care and oncology optimized distribution models as vital strategies to improve outcomes, streamline access, and reduce costs for patients.

BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Here's a list of the companies that have announced new U.S. investments since Trump took office: Merck on Tuesday said it is ...

Business & Finance Media Group in partnership with Ibec has launched the Top 100 Companies Leading In Wellbeing Index 2025.

This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings ...